Timothy Langford, MD
Urology · Little Rock, ARNPI 1902871627
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $122,000 of the $132,918 with a category attached, or 91.8%. Cryo Specialty Medical, LLC accounts for 91.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $40,269 and has fallen 99.4% since, to $235 in 2025. Among urology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $479.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cryo Specialty Medical, LLC$122K
- Palette Life Sciences, Inc.$2K
- Coloplast$1K
- Neotract Inc.$992
- Teleflex LLC$931
- Boston Scientific$922
- plus $5K from 29 others
Across 11 payments — averaging $4274.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$47K
What the payments were for
- Travel & lodging$3,9043%
- Food & beverage$6,9505%
- Education$640%
- Ownership interest$122,00092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cryo Specialty Medical, LLC | 4 | $122,000 |
| Palette Life Sciences, Inc. | 5 | $2,108 |
| Coloplast | 32 | $1,024 |
| Neotract Inc. | 10 | $992 |
| Teleflex LLC | 10 | $931 |
| Boston Scientific | 21 | $922 |
| Procept Biorobotics Corporation | 10 | $818 |
| Intuitive Surgical | 6 | $722 |
| Astellas Pharma US Inc | 20 | $472 |
| Pfizer | 30 | $455 |
| AbbVie(2 entities) | 23 | $365 |
| Dendreon Pharmaceuticals LLC | 13 | $316 |
| Johnson & Johnson | 22 | $243 |
| Blue Earth Diagnostics | 8 | $185 |
| Rochester Medical Corporation | 9 | $161 |
| Myovant Sciences Inc. | 8 | $143 |
| Endo Pharmaceuticals Inc. | 3 | $142 |
| Merck | 3 | $124 |
| AstraZeneca | 2 | $101 |
| Amgen | 6 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $86 |
| Ambu Inc. | 3 | $73 |
| Bayer | 5 | $69 |
| Myriad Genetic Laboratories, Inc. | 4 | $68 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Davol Inc. | 2 | $41 |
| Innovation Technologies Inc | 1 | $39 |
| Axonics, Inc. | 2 | $29 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 2 | $23 |
| Baudax Bio Inc. | 1 | $23 |
| KARL Storz Endoscopy-america | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Clovis Oncology, Inc. | 1 | $16 |
| EDAP Technomed Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,399
- Da Vinci Surgical System$597
- AquaBeam Robotic System$572
- TITAN$364
- GENERAL ERECTILE DYSFUNCTION$230
- UroLift System$123
- XTANDI$113
- XIAFLEX$113
How this compares
$132,918 in reported general payments places this provider in the 90th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $256,148 |
| MyrbetriqMirabegron | 42 | $30,963 |
| Trospium Chloride | 43 | $4,324 |
| Tamsulosin Hcl | 150 | $2,314 |
| Solifenacin Succinate | 13 | $1,341 |
| Finasteride | 101 | $1,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $472 | $287,11166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- John MooreLittle Rock$19K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
- Marcelo BigarellaLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.